HC Wainwright Forecasts MetaVia FY2030 Earnings

MetaVia Inc. (NASDAQ:MTVA) – HC Wainwright issued their FY2030 earnings estimates for shares of MetaVia in a research report issued to clients and investors on Tuesday, January 6th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.65) for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($2.86) by $1.32.

MTVA has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Wall Street Zen raised shares of MetaVia to a “sell” rating in a report on Saturday, January 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $36.50.

MetaVia Stock Performance

NASDAQ MTVA opened at $8.77 on Thursday. The business’s fifty day moving average is $8.80 and its 200 day moving average is $8.73. MetaVia has a fifty-two week low of $6.05 and a fifty-two week high of $25.30. The company has a market capitalization of $19.29 million, a PE ratio of -1.05 and a beta of 0.27.

Institutional Investors Weigh In On MetaVia

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC lifted its holdings in MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,386 shares of the company’s stock after acquiring an additional 18,506 shares during the period. SG Americas Securities LLC owned 0.25% of MetaVia worth $57,000 at the end of the most recent reporting period. 1.37% of the stock is owned by institutional investors and hedge funds.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.